Daiichi Sankyo Company, Limited

Japan Tobacco Inc.

Kabushiki Kaisha Audio Technica

Yuki Abe

Takeshi Masuda

Hiroyuki Naito

Masao Yoshida

Yuji Kasuya

Takashi Nakada

Shinji Ashida

Yusuke Ogitani

Koji Morita

Michihiro Inagaki

Ichiro Hayakawa

Simon Cox

Franck Rubiconi

Takahisa Kudo

Jumpei Inoue

Adam Geernaert

Yuki Minami

Rishi Jobanputra

Miki Wakamatsu

Tatsuya Suganuma

Osamu Yokoi

As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an antibody via a linker having a structure represented by the following formula: -L-L-L-NH—(CH)n-L-L-L- wherein the antibody is connected to the terminal of L, and the antitumor compound is connected to the terminal of Lwith the nitrogen atom of the amino group at position 1 as a connecting position.

Antibody-drug conjugate

An aerosol supply device includes: an accommodating part (cartridge) configured to accommodate a liquid; an atomization unit having a storing part to store the liquid, the atomization unit being configured to generate an aerosol by atomizing the liquid; and a temperature control part configured to control the temperature of the liquid at a given location between the accommodating part (cartridge) and the storing part.

Temperature controlled aerosol supply device

This aerosol supply device is provided with: an accommodating section (cartridge) that accommodates a liquid; an atomizing unit that atomizes the liquid to generate an aerosol; and an atomizing amount adjusting unit (gyro sensor and control unit) that adjusts the atomizing amount of the atomizing unit. The aerosol supply device is characterized in that the atomizing amount adjusting unit (gyro sensor and control unit) stabilizes the atomizing amount regardless of the inclination of the aerosol supply device within at least a certain range.

Aerosol supply device

An inhaler includes an atomizing unit including a piezoelectric element substrate having a first IDT including a pair of interlocking comb-shaped electrodes. The atomizing unit is configured to atomize liquid by a surface acoustic wave generated by applying a high-frequency voltage to the pair of interlocking comb-shaped electrodes, and a controller is configured to monitor a resonant frequency of the pair of interlocking comb-shaped electrodes and apply a voltage to the pair of interlocking comb-shaped electrodes at a frequency determined based on the monitored resonant frequency.

Inhaler

A controller for controlling an atomizing unit, wherein the atomizing unit includes a piezoelectric element substrate including an IDT including a pair of interlocking comb-shaped metallic electrodes, and a liquid supplier configured to supply liquid, which is to be atomized, to the piezoelectric element substrate; wherein the piezoelectric element substrate is configured to atomize the liquid by use of a surface acoustic wave generated by applying a high-frequency voltage to the pair of interlocking comb-shaped metallic electrodes; and the controller is configured to periodically change amplitude and/or a frequency of the high-frequency voltage applied to the pair of interlocking comb-shaped metallic electrodes.

A inhaler includes a piezoelectric element substrate having an IDT constructed by use of a pair of interlocking comb-shaped metallic electrodes, a liquid supplier for supplying liquid, which is to be atomized, to a front surface of the piezoelectric element substrate on which the pair of interlocking comb-shaped metallic electrodes is positioned, a sensor, which includes at least a pair of detection parts which are opposite to each other, for detecting liquid supplied to the front surface of the piezoelectric element substrate, and a controller for controlling, based on result of detection by the sensor, the liquid supplier in such a manner that the liquid supplier supplies a certain quantity of the liquid to the front surface of the piezoelectric element substrate.

Flavor inhaler

As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the following formula: -L-L-L-NH&#x2014;(CH)n-L-(CH)n-C(&#x2550;O)&#x2014; wherein the anti-HER2 antibody is connected to the terminal L, and the antitumor compound is connected to the carbonyl group of the &#x2014;(CH)n-C(&#x2550;O)&#x2014; moiety with the nitrogen atom of the amino group at position 1 as the connecting position

Method for treating cancer comprising administration of anti-HER2 antibody-drug conjugate

As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an antibody via a linker having a structure represented by the following formula: -L-L-L-NH&#x2014;(CH)n-L-L-L- wherein the antibody is connected to the terminal of L, and the antitumor compound is connected to the terminal of Lwith the nitrogen atom of the amino group at position 1 as a connecting position.

As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the following formula: -L-L-L-NH&#x2014;(CH)n-L-(CH)n-C(&#x2550;O)&#x2014; wherein the anti-HER2 antibody is connected to the terminal L, and the antitumor compound is connected to the carbonyl group of the &#x2014;(CH)n-C(&#x2550;O)&#x2014; moiety with the nitrogen atom of the amino group at position 1 as the connecting position. 

Method of treating cancer comprising administration of anti-HER2 antibody-drug conjugate

As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the formula: L-L-L-NH&#x2014;(CH)n-L-L-Lor -L-L-L- wherein the anti-HER2 antibody is connected to the terminal L, and the antitumor compound is connected to the terminal Lor Lwith the nitrogen atom of the amino group at position 1 as the connecting position. 

(Anti-HER2 antibody)-drug conjugate

As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula (I) is conjugated to an antibody via a linker having a structure represented by the following formula: -L-L-L-NH&#x2014;(CH)n-L-L-L- or -L-L-L- wherein the antibody is connected to the terminal of L, the antitumor compound is connected to the terminal of Lor L, and any one or two or more of linkers of L, L, and Lhas a hydrophilic structure.

Antibody-drug conjugate produced by binding through linker having hydrophilic structure

As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an antibody via a linker having a structure represented by the following formula:-L-L-L-NH&#x2014;(CH)-L-L-L-wherein the antibody is connected to the terminal of L, and the antitumor compound is connected to the terminal of Lwith the nitrogen atom of the amino group at position 1 as a connecting position.

Growing community of inventors

Tokyo, Japan

Yuki Abe